Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)

Dr. Robert A. Montgomery

Transplant Surgery | General Surgery
New York University
530 1st Ave, 
New York, NY 
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
New York University
530 1st Ave, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Robert Montgomery is a Transplant Surgeon and a General Surgeon in New York, New York. Dr. Montgomery is rated as an Experienced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are End-Stage Renal Disease (ESRD), Hepatitis, Chronic Antibody-Mediated Rejection, Kidney Transplant, and Simultaneous Pancreas Kidney Transplant.

His clinical research consists of co-authoring 274 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Atypical Hemolytic Uremic Syndrome (aHUS).

Specialties
Transplant Surgery
General Surgery
Licenses
Surgery in MD
Hospital Affiliations
Nyu Langone Hospitals
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

NEW YORK UNIVERSITY
530 1st Ave, New York, NY 10016
Other Locations
NEW YORK UNIVERSITY
1999 Marcus Ave, Suite 120, New Hyde Park, NY 11042
NEW YORK UNIVERSITY
111 Broadway, New York, NY 10006

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC
An Open-label, Controlled, Randomized Phase 3 Trial Evaluating 12-month Kidney Function in Highly Sensitized (cPRA ≥99.9%) Kidney Tx Patients With Positive XM Against a Deceased Donor, Comparing Desensitization Using Imlifidase With SoC
Enrollment Status: Completed
Publish Date: July 16, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Imlifidase, IVIg, Anti-CD20 Antibodies, Eculizumab
Study Phase: Phase 3
A Prospective Observational, Long Term Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
A Prospective Observational, Long Term Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Enrollment Status: Completed
Publish Date: February 07, 2025
Intervention Type: Drug
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
A Randomized, Open-Label, Multi-Centre, Active Control, Efficacy and Safety Study of Imlifidase in Eliminating Donor Specific Anti-HLA Antibodies in the Treatment of Active Antibody-Mediated Rejection in Kidney Transplant Patients
Enrollment Status: Completed
Publish Date: February 28, 2024
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test
A Phase II Study to Evaluate the Efficacy of IdeS (IgG Endopeptidase) to Desensitize Transplant Patients With a Positive Crossmatch Test
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug, Procedure
Study Phase: Phase 2
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinryze® (C1 Esterase Inhibitor [Human]) for the Treatment of Acute Antibody-mediated Rejection in Kidney Transplant Patients
Enrollment Status: Terminated
Publish Date: July 13, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 3
Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Open Label Randomized Study of Thymoglobulin Versus Daclizumab Induction Therapies for the Reduction of Acute Rejection in Live Donor Kidney Transplant Recipients With a Positive Crossmatch
Enrollment Status: Completed
Publish Date: January 18, 2018
Intervention Type: Drug, Other
Study Phase: Phase 3
View 5 Less Clinical Trials
Similar Doctors
Advanced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Bernd Schroppel
Nephrology | Transplant Surgery
Advanced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Bernd Schroppel
Nephrology | Transplant Surgery
5 E 98th St, 12th Flr, 
New York, NY 
 (3.4 miles away)
212-241-4060
Languages Spoken:
English

Bernd Schroppel is a Nephrologist and a Transplant Surgeon in New York, New York. Dr. Schroppel is rated as an Advanced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), Kidney Transplant, and Liver Transplant.

Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Tsiporah B. Shore
Oncology | Hematology | Transplant Surgery
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Tsiporah B. Shore
Oncology | Hematology | Transplant Surgery

Weill Medical College Of Cornell

520 E 70th St, 
New York, NY 
 (2.0 miles away)
212-746-2467
Languages Spoken:
English
See accepted insurances

Tsiporah Shore is an Oncologist and a Hematologist in New York, New York. Dr. Shore is rated as a Distinguished provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Adrienne A. Phillips
Hematology Oncology | Oncology | Transplant Surgery
Experienced in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Adrienne A. Phillips
Hematology Oncology | Oncology | Transplant Surgery

Barnabas Health Medical Group PC

94 Old Short Hills Rd, 
Livingston, NJ 
 (17.3 miles away)
973-322-7000
Languages Spoken:
English
See accepted insurances

Adrienne Phillips is a Hematologist Oncology specialist and an Oncologist in Livingston, New Jersey. Dr. Phillips is rated as a Distinguished provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). Her top areas of expertise are Adult T-Cell Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Montgomery's expertise for a condition
ConditionClose
    View All 15 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile